A framework enabling LLMs into regulatory environment for transparency and trustworthiness and its application to drug labeling document
Open Access
- 2 April 2024
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 149, 105613
Abstract
No abstract availableKeywords
Funding Information
- US FDA
This publication has 6 references indexed in Scilit:
- RxBERT: Enhancing drug labeling text mining and analysis with AI language modelingExperimental Biology and Medicine, 2023
- PharmBERT: a domain-specific BERT model for drug labelsBriefings in Bioinformatics, 2023
- Beware of references when using ChatGPT as a source of information to write scientific articlesAmerican Journal of Obstetrics and Gynecology, 2023
- An era of ChatGPT as a significant futuristic support tool: A study on features, abilities, and challengesBenchCouncil Transactions on Benchmarks, Standards and Evaluations, 2022
- FDALabel for drug repurposing studies and beyondNature Biotechnology, 2020
- FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory scienceDrug Discovery Today, 2016